- Home
- MYGN vs CHI Comparison
MYGN vs CHI Comparison
Compare MYGN & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CHI
- Stock Information
- Founded
- MYGN 1991
- CHI 2002
- Country
- MYGN United States
- CHI United States
- Employees
- MYGN N/A
- CHI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CHI Investment Managers
- Sector
- MYGN Health Care
- CHI Finance
- Exchange
- MYGN Nasdaq
- CHI Nasdaq
- Market Cap
- MYGN 744.7M
- CHI 801.3M
- IPO Year
- MYGN 1995
- CHI N/A
- Fundamental
- Price
- MYGN $5.34
- CHI $10.49
- Analyst Decision
- MYGN Hold
- CHI
- Analyst Count
- MYGN 15
- CHI 0
- Target Price
- MYGN $15.14
- CHI N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- CHI 186.2K
- Earning Date
- MYGN 08-05-2025
- CHI 01-01-0001
- Dividend Yield
- MYGN N/A
- CHI 9.90%
- EPS Growth
- MYGN N/A
- CHI N/A
- EPS
- MYGN N/A
- CHI N/A
- Revenue
- MYGN $831,300,000.00
- CHI N/A
- Revenue This Year
- MYGN N/A
- CHI N/A
- Revenue Next Year
- MYGN $6.68
- CHI N/A
- P/E Ratio
- MYGN N/A
- CHI N/A
- Revenue Growth
- MYGN 7.38
- CHI N/A
- 52 Week Low
- MYGN $3.81
- CHI $9.70
- 52 Week High
- MYGN $29.30
- CHI $11.61
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- CHI 60.35
- Support Level
- MYGN $4.90
- CHI $10.00
- Resistance Level
- MYGN $5.83
- CHI $10.60
- Average True Range (ATR)
- MYGN 0.28
- CHI 0.09
- MACD
- MYGN 0.04
- CHI 0.01
- Stochastic Oscillator
- MYGN 54.21
- CHI 78.45
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.